Altimmune ($ALT) now has FDA Breakthrough Therapy Designation and positive Phase 2 data for pemvidutide. How realistic is a near-term partnership or buyout before Phase 3, and what valuation range do you think big pharma would consider based on past BTD biotech acquisitions?